Personal tools

DOID:0050686

From FANTOM5_SSTAR

Revision as of 13:58, 11 June 2012 by Autoedit (talk | contribs)
Jump to: navigation, search

Name:organ system cancer
Namespace:disease_ontology
Definition:"A cancer that is classified based on the organ it starts in." [url:http\://cancerguide.org/basic.html]
Created by:snadendla
Creation date:2011-06-13T03:28:33Z

Ontology association<br>Each term has an is_a parent in the Disease Ontology, which has a linkage to an another entity and FANTOM5 samples.Libraries were grouped into mutually exclusive facets according to the FANTOM5 sample ontology mapping to DISEASE ontologies.<br><br>link to ontology dataset<br>data

Parents

is_a:DOID:162(cancer)



Children


is a:DOID:0050615 (respiratory system cancer),DOID:0060083 (immune system cancer),DOID:0060100 (musculoskeletal system cancer),DOID:0060122 (integumentary system cancer),DOID:170 (endocrine gland cancer),DOID:193 (reproductive organ cancer),DOID:3093 (nervous system cancer),DOID:3119 (gastrointestinal system cancer),DOID:3996 (urinary system cancer),DOID:5093 (thoracic cancer)

Ontology Tree: Loaded from BioPortal

Ontorolgy tree(Small window open)

FF samples

Human (Homo sapiens)

  • 10399-106A3 (acute myeloid leukemia (FAB M5) cell line:THP-1 (fresh))
  • 10400-106A4 (acute myeloid leukemia (FAB M5) cell line:THP-1 (revived))
  • 10405-106A9 (acute myeloid leukemia (FAB M5) cell line:THP-1 (thawed))
  • 10408-106B3 (lung adenocarcinoma cell line:PC-14)
  • 10409-106B4 (chronic myelogenous leukemia cell line:KU812)
  • 10410-106B5 (extraskeletal myxoid chondrosarcoma cell line:H-EMC-SS)
  • 10413-106B8 (glioma cell line:GI-1)
  • 10414-106B9 (maxillary sinus tumor cell line:HSQ-89)
  • 10416-106C2 (chronic lymphocytic leukemia (T-CLL) cell line:SKW-3)
  • 10417-106C3 (papillotubular adenocarcinoma cell line:TGBC18TKB)

... further results Mouse (Mus musculus)

  • 10399-106A3 (acute myeloid leukemia (FAB M5) cell line:THP-1 (fresh))
  • 10400-106A4 (acute myeloid leukemia (FAB M5) cell line:THP-1 (revived))
  • 10405-106A9 (acute myeloid leukemia (FAB M5) cell line:THP-1 (thawed))
  • 10408-106B3 (lung adenocarcinoma cell line:PC-14)
  • 10409-106B4 (chronic myelogenous leukemia cell line:KU812)
  • 10410-106B5 (extraskeletal myxoid chondrosarcoma cell line:H-EMC-SS)
  • 10413-106B8 (glioma cell line:GI-1)
  • 10414-106B9 (maxillary sinus tumor cell line:HSQ-89)
  • 10416-106C2 (chronic lymphocytic leukemia (T-CLL) cell line:SKW-3)
  • 10417-106C3 (papillotubular adenocarcinoma cell line:TGBC18TKB)

... further results

Enrichment analysis: top 100 FFCP enriched with this ontology termTOP 100 FANTOM5 Cage Peaks enriched with DOID:0050686 (organ system cancer), sorted by p-values <br>Analyst: Hideya Kawaji<br><br>link to source dataset <br>human : data <br>mouse : data

P-valueFFCPShort description
5.38e-44FFCP PHASE2:Mm9::chr10:76688454..76688462,+#_65285b631ec8e691fc425814dcf2d967p@chr10:76688454..76688462, +
5.38e-44FFCP PHASE1:Mm9::chr10:76688464..76688474,+#_65285b631ec8e691fc425814dcf2d967p@chr10:76688464..76688474, +
5.38e-44FFCP PHASE2:Mm9::chr1:180919481..180919491,-#_65285b631ec8e691fc425814dcf2d967p4@Smyd3
5.38e-44FFCP PHASE1:Mm9::chr11:102331415..102331424,-#_65285b631ec8e691fc425814dcf2d967p9@Itga2b
5.38e-44FFCP PHASE2:Mm9::chr10:76688464..76688474,+#_65285b631ec8e691fc425814dcf2d967p@chr10:76688464..76688474, +
5.38e-44FFCP PHASE1:Mm9::chr1:180919481..180919491,-#_65285b631ec8e691fc425814dcf2d967p4@Smyd3
5.38e-44FFCP PHASE1:Mm9::chr10:76688454..76688462,+#_65285b631ec8e691fc425814dcf2d967p@chr10:76688454..76688462, +
5.38e-44FFCP PHASE2:Mm9::chr11:102331415..102331424,-#_65285b631ec8e691fc425814dcf2d967p9@Itga2b
7.84e-44FFCP PHASE2:Mm9::chr5:73305337..73305352,-#_692df3654ca27a8dd5299c8ed7b16e10p@chr5:73305337..73305352, -
7.84e-44FFCP PHASE1:Mm9::chr5:73305337..73305352,-#_692df3654ca27a8dd5299c8ed7b16e10p@chr5:73305337..73305352, -
4.79e-40FFCP PHASE2:Hg19::chr6:135513595..135513617,+#_ed865de4e8270344eabaddd1590e4f5dp4@MYB
4.79e-40FFCP PHASE1:Hg19::chr6:135513595..135513617,+#_ed865de4e8270344eabaddd1590e4f5dp4@MYB
4.3e-38FFCP PHASE1:Hg19::chr2:197504410..197504471,+#_ffbffa6d6a72381ab7b91b96b0a55359p1@CCDC150
4.3e-38FFCP PHASE2:Hg19::chr2:197504410..197504471,+#_ffbffa6d6a72381ab7b91b96b0a55359p1@CCDC150
7.41e-38FFCP PHASE1:Hg19::chr11:1372935..1372952,+#_8a80ee5033771369a6e0ad8692a57a1cp@chr11:1372935..1372952, +
7.41e-38FFCP PHASE2:Hg19::chr11:1372935..1372952,+#_8a80ee5033771369a6e0ad8692a57a1cp@chr11:1372935..1372952, +
2.52e-35FFCP PHASE2:Hg19::chrX:153991088..153991168,+#_1c5c0a174c081d5c665610633d5fdf02p1@DKC1
2.52e-35FFCP PHASE1:Hg19::chrX:153991088..153991168,+#_1c5c0a174c081d5c665610633d5fdf02p1@DKC1
1.76e-34FFCP PHASE2:Hg19::chr6:41513920..41513957,-#_06da1f80d7a37d2a8e3d7e6a717c7595p1@ENST00000414386
1.76e-34FFCP PHASE1:Hg19::chr6:41513920..41513957,-#_06da1f80d7a37d2a8e3d7e6a717c7595p1@ENST00000414386
4.66e-34FFCP PHASE2:Hg19::chr14:23120305..23120309,+#_1b72c822d2a7235e1ea2e9fbd6d67218p@chr14:23120305..23120309, +
4.66e-34FFCP PHASE1:Hg19::chr14:23120305..23120309,+#_1b72c822d2a7235e1ea2e9fbd6d67218p@chr14:23120305..23120309, +
1.36e-33FFCP PHASE1:Mm9::chr11:70246799..70246835,-#_1ce09872001252dca1a2235b12c6e8bap@chr11:70246799..70246835, -
1.36e-33FFCP PHASE2:Mm9::chr11:70246799..70246835,-#_1ce09872001252dca1a2235b12c6e8bap@chr11:70246799..70246835, -
2.03e-33FFCP PHASE1:Mm9::chr19:8798483..8798487,+#_5eb2fd793321ac0bee0ac8986210400ep1@ENSMUST00000082787
2.03e-33FFCP PHASE1:Mm9::chrX:160480258..160480272,-#_5eb2fd793321ac0bee0ac8986210400ep@chrX:160480258..160480272, -
2.03e-33FFCP PHASE2:Mm9::chr19:8798483..8798487,+#_5eb2fd793321ac0bee0ac8986210400ep1@ENSMUST00000082787
2.03e-33FFCP PHASE1:Mm9::chr2:156853485..156853494,-#_5eb2fd793321ac0bee0ac8986210400ep13@9830001H06Rik
2.03e-33FFCP PHASE2:Mm9::chr2:156853485..156853494,-#_5eb2fd793321ac0bee0ac8986210400ep13@9830001H06Rik
2.03e-33FFCP PHASE2:Mm9::chrX:160480258..160480272,-#_5eb2fd793321ac0bee0ac8986210400ep@chrX:160480258..160480272, -
2.62e-33FFCP PHASE1:Hg19::chr22:35627045..35627052,-#_61b3ebe3094780960c50cee7e9e36d6ep1@ENST00000423311
2.62e-33FFCP PHASE2:Hg19::chr22:35627045..35627052,-#_61b3ebe3094780960c50cee7e9e36d6ep1@ENST00000423311
3.55e-33FFCP PHASE2:Mm9::chr6:88785201..88785204,+#_d8b56478c34cacad67d52c59162772bfp@chr6:88785201..88785204, +
3.55e-33FFCP PHASE1:Mm9::chr6:88785201..88785204,+#_d8b56478c34cacad67d52c59162772bfp@chr6:88785201..88785204, +
4.33e-33FFCP PHASE2:Mm9::chr10:94309614..94309618,+#_0281bec43ce70fe4889c6a3a8609accep@chr10:94309614..94309618, +
4.33e-33FFCP PHASE1:Mm9::chr12:32681792..32681797,-#_0281bec43ce70fe4889c6a3a8609accep@chr12:32681792..32681797, -
4.33e-33FFCP PHASE1:Mm9::chr10:94309614..94309618,+#_0281bec43ce70fe4889c6a3a8609accep@chr10:94309614..94309618, +
4.33e-33FFCP PHASE2:Mm9::chr12:32681792..32681797,-#_0281bec43ce70fe4889c6a3a8609accep@chr12:32681792..32681797, -
5.3e-33FFCP PHASE1:Hg19::chr3:121264813..121264846,-#_8255802812d0270ace3de92af7817696p1@POLQ
5.3e-33FFCP PHASE2:Hg19::chr3:121264813..121264846,-#_8255802812d0270ace3de92af7817696p1@POLQ
5.56e-33FFCP PHASE2:Hg19::chr8:124408652..124408712,-#_d00b11a8edef26551750eaa512fe019cp1@ATAD2
5.56e-33FFCP PHASE1:Hg19::chr8:124408652..124408712,-#_d00b11a8edef26551750eaa512fe019cp1@ATAD2
6.96e-33FFCP PHASE2:Hg19::chr18:19192235..19192337,+#_ca9b966b07899bd7fb53e3b35305b862p1@SNRPD1
6.96e-33FFCP PHASE1:Hg19::chr18:19192235..19192337,+#_ca9b966b07899bd7fb53e3b35305b862p1@SNRPD1
2.93e-32FFCP PHASE1:Hg19::chr4:154265825..154265875,+#_9ac8fcdefc18be3500c030e58a78330ap1@MND1
2.93e-32FFCP PHASE2:Hg19::chr4:154265825..154265875,+#_9ac8fcdefc18be3500c030e58a78330ap1@MND1
8.35e-32FFCP PHASE2:Hg19::chr6:135533394..135533403,+#_9f829c22357e438ca6e62c2760691497p@chr6:135533394..135533403, +
8.35e-32FFCP PHASE1:Hg19::chr6:135533394..135533403,+#_9f829c22357e438ca6e62c2760691497p@chr6:135533394..135533403, +
1.02e-31FFCP PHASE2:Hg19::chr11:125495862..125495882,+#_c3eb4dbbd38174c485fe1eccf3a0a6bep1@CHEK1
1.02e-31FFCP PHASE1:Hg19::chr11:125495862..125495882,+#_c3eb4dbbd38174c485fe1eccf3a0a6bep1@CHEK1
1.35e-31FFCP PHASE2:Hg19::chrX:153991175..153991226,+#_10e3ca8bff31be45949587c957f6f80dp2@DKC1
1.35e-31FFCP PHASE1:Hg19::chrX:153991175..153991226,+#_10e3ca8bff31be45949587c957f6f80dp2@DKC1
2.12e-31FFCP PHASE2:Hg19::chr17:38574169..38574180,-#_92844aa3829cee8c596d9f02fece6218p2@TOP2A
2.12e-31FFCP PHASE1:Hg19::chr17:38574169..38574180,-#_92844aa3829cee8c596d9f02fece6218p2@TOP2A
2.29e-31FFCP PHASE2:Hg19::chr1:154947126..154947147,+#_268ecb80cbcbf09a077b87bd2c03bc35p2@CKS1B
2.29e-31FFCP PHASE1:Hg19::chr1:154947126..154947147,+#_268ecb80cbcbf09a077b87bd2c03bc35p2@CKS1B
2.82e-31FFCP PHASE2:Hg19::chr15:40453204..40453304,+#_e53cbafc8df2e5636b114fa96c46e46ep1@BUB1B
2.82e-31FFCP PHASE1:Hg19::chr15:40453204..40453304,+#_e53cbafc8df2e5636b114fa96c46e46ep1@BUB1B
3.73e-31FFCP PHASE1:Hg19::chr2:70529150..70529179,-#_ba0e0d38c9ba42da3d9baec6adada094p1@FAM136A
3.73e-31FFCP PHASE2:Hg19::chr2:70529150..70529179,-#_ba0e0d38c9ba42da3d9baec6adada094p1@FAM136A
4.02e-31FFCP PHASE2:Hg19::chr3:179280702..179280769,+#_513fffec3ea7750a37c11bb08b6c6582p1@ACTL6A
4.02e-31FFCP PHASE1:Hg19::chr3:179280702..179280769,+#_513fffec3ea7750a37c11bb08b6c6582p1@ACTL6A
4.81e-31FFCP PHASE1:Hg19::chr17:41393591..41393606,+#_654b400a2735702310dcc2dfb5657c3bp@chr17:41393591..41393606, +
4.81e-31FFCP PHASE2:Hg19::chr17:41393591..41393606,+#_654b400a2735702310dcc2dfb5657c3bp@chr17:41393591..41393606, +
1.26e-30FFCP PHASE1:Hg19::chr1:214776516..214776565,+#_a677ddc3db1a54571c6beaac689af18fp1@CENPF
1.26e-30FFCP PHASE2:Hg19::chr1:214776516..214776565,+#_a677ddc3db1a54571c6beaac689af18fp1@CENPF
1.44e-30FFCP PHASE2:Hg19::chr17:41277372..41277418,-#_2fddfddd419b2d6f6106fb406cd214e9p1@BRCA1
1.44e-30FFCP PHASE1:Hg19::chr17:41277372..41277418,-#_2fddfddd419b2d6f6106fb406cd214e9p1@BRCA1
1.59e-30FFCP PHASE1:Hg19::chr4:57301645..57301675,-#_0e4d027910a29ed530404658594af835p2@PPAT
1.59e-30FFCP PHASE2:Hg19::chr4:57301645..57301675,-#_0e4d027910a29ed530404658594af835p2@PPAT
1.99e-30FFCP PHASE1:Hg19::chr22:22901636..22901715,-#_f13d97b6742b34a17e98c6ab8ced2e6cp1@PRAME
1.99e-30FFCP PHASE2:Hg19::chr22:22901636..22901715,-#_f13d97b6742b34a17e98c6ab8ced2e6cp1@PRAME
2.37e-30FFCP PHASE1:Hg19::chr4:185655212..185655260,-#_e9cd57d633552c37406e9d0bb31f648dp1@MLF1IP
2.37e-30FFCP PHASE2:Hg19::chr4:185655212..185655260,-#_e9cd57d633552c37406e9d0bb31f648dp1@MLF1IP
2.72e-30FFCP PHASE2:Hg19::chr2:70529180..70529217,-#_8e0be7bd25fb47f538f26925905fbbe0p2@FAM136A
2.72e-30FFCP PHASE1:Hg19::chr2:70529180..70529217,-#_8e0be7bd25fb47f538f26925905fbbe0p2@FAM136A
3.23e-30FFCP PHASE1:Hg19::chr17:38574125..38574168,-#_f0a362f500013fb62301a13901bc45adp1@TOP2A
3.23e-30FFCP PHASE2:Hg19::chr17:38574125..38574168,-#_f0a362f500013fb62301a13901bc45adp1@TOP2A
3.86e-30FFCP PHASE1:Hg19::chr1:200589859..200589887,-#_880ce44e6f10e2ba2bff1b4af9152386p1@KIF14
3.86e-30FFCP PHASE2:Hg19::chr1:200589859..200589887,-#_880ce44e6f10e2ba2bff1b4af9152386p1@KIF14
4.12e-30FFCP PHASE1:Hg19::chr1:46713405..46713452,+#_5fa6a84caee6edd38ef67bf00e288123p1@RAD54L
4.12e-30FFCP PHASE2:Hg19::chr1:46713405..46713452,+#_5fa6a84caee6edd38ef67bf00e288123p1@RAD54L
6.66e-30FFCP PHASE2:Mm9::chr11:104171122..104171127,+#_2dbe02d97ddb9048aeba52fa04ae6158p@chr11:104171122..104171127, +
6.66e-30FFCP PHASE1:Mm9::chr11:104171122..104171127,+#_2dbe02d97ddb9048aeba52fa04ae6158p@chr11:104171122..104171127, +
7.27e-30FFCP PHASE2:Hg19::chr7:105162652..105162709,-#_9b66c6c4540d5ce1ff8804acfd5f8506p1@PUS7
7.27e-30FFCP PHASE1:Hg19::chr7:105162652..105162709,-#_9b66c6c4540d5ce1ff8804acfd5f8506p1@PUS7
1.83e-29FFCP PHASE2:Hg19::chr6:135502472..135502489,+#_9e9040d9604b80e2dc6b93b799617849p3@MYB
1.83e-29FFCP PHASE1:Hg19::chr6:135502472..135502489,+#_9e9040d9604b80e2dc6b93b799617849p3@MYB
1.97e-29FFCP PHASE2:Hg19::chr15:41672357..41672421,+#_587a38a7cddead91f8f0365c91964e87p@chr15:41672357..41672421, +
1.97e-29FFCP PHASE1:Hg19::chr15:41672357..41672421,+#_587a38a7cddead91f8f0365c91964e87p@chr15:41672357..41672421, +
2.03e-29FFCP PHASE1:Mm9::chr11:79436622..79436627,-#_fe06aa258f9ee5c87f22314813ed6676p1@Gm11202
2.03e-29FFCP PHASE2:Mm9::chr11:79436622..79436627,-#_fe06aa258f9ee5c87f22314813ed6676p1@Gm11202
2.34e-29FFCP PHASE2:Hg19::chr10:58120996..58121039,-#_be386d87003b552e631ec3f5c02d5824p1@ZWINT
2.34e-29FFCP PHASE1:Hg19::chr10:58120996..58121039,-#_be386d87003b552e631ec3f5c02d5824p1@ZWINT
2.62e-29FFCP PHASE1:Hg19::chr4:154265784..154265819,+#_6eab4cf42b85fc672bfdc11f454d4d4ep2@MND1
2.62e-29FFCP PHASE2:Hg19::chr4:154265784..154265819,+#_6eab4cf42b85fc672bfdc11f454d4d4ep2@MND1
2.69e-29FFCP PHASE1:Hg19::chr12:102514019..102514035,+#_9e31a9098b95749f7ab2336195c7d568p3@C12orf48
2.69e-29FFCP PHASE2:Hg19::chr12:102514019..102514035,+#_9e31a9098b95749f7ab2336195c7d568p3@C12orf48
2.75e-29FFCP PHASE1:Hg19::chr20:57617831..57617909,-#_34dd3003a516034e15fb4789c3fc8a80p1@SLMO2
2.75e-29FFCP PHASE2:Hg19::chr20:57617831..57617909,-#_34dd3003a516034e15fb4789c3fc8a80p1@SLMO2

Retrieved from "http://f5-webapp4.gsc.riken.jp/resource_browser/index.php?title=DOID:0050686&oldid=1832140"